NCT02105701View on ClinicalTrials.gov

Study of Efficacy and Safety of Grazoprevir (MK-5172) + Elbasvir (MK-8742) With or Without Ribavirin for Participants With Hepatitis C Genotype 1, 4, or 6 Infections Who Have Failed Prior Treatment With Pegylated Interferon + Ribavirin (MK-5172-068)

PHASE3CompletedINTERVENTIONAL

Enrollment

420

Participants

Timeline

Start Date

June 5, 2014

Primary Completion Date

March 24, 2015

Study Completion Date

June 19, 2015

Conditions

Hepatitis C Infection

Interventions

DRUG

Grazoprevir + Elbasvir

FDC tablet containing grazoprevir 100 mg and elbasvir 50 mg.

DRUG

Ribavirin

200 mg capsule

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT02105701 - Study of Efficacy and Safety of Grazoprevir (MK-5172) + Elbasvir (MK-8742) With or Without Ribavirin for Participants With Hepatitis C Genotype 1, 4, or 6 Infections Who Have Failed Prior Treatment With Pegylated Interferon + Ribavirin (MK-5172-068) | Biotech Hunter | Biotech Hunter